For French biotech and pharmaceutical companies, the French Research Tax Credit (CIR - Crédit d’Impôt Recherche) is a powerful tool for managing R&D investment. What many teams don’t realise is that CIR benefits can still apply even when R&D is outsourced outside France - as long as the work is performed by a CRO accredited under the CIR scheme.
hVIVO’s German operations are now officially CIR‑accredited for 2026-2028 across three operational units. Combined with our CIR‑accredited biometrics office in France, this creates a seamless, fully eligible pathway for French sponsors to access hVIVO’s integrated early‑phase capabilities across Europe.
Why this matters: CIR as part of a broader
early-phase strategy
At hVIVO, we’ve built a purpose‑designed early‑phase engine: consultancy, laboratories, clinical delivery, and recruitment working as one integrated platform. CIR accreditation adds another component to that engine - one that directly benefits French innovators.
It means French sponsors can access specialised early‑phase expertise in Germany while maintaining CIR eligibility on qualifying R&D activities. In practice, this reduces effective R&D costs without compromising on scientific depth, operational quality, or timelines. .
European expertise, CIR‑eligible work
Our German teams bring decades of experience in early‑phase clinical development, biometrics, and operational delivery across multiple therapeutic areas. With CIR accreditation in place, French companies can:
- work with a specialised European CRO
- maintain CIR eligibility on qualifying outsourced R&D
- accelerate early‑phase timelines through our integrated model
- collaborate across borders with harmonised processes and regulatory alignment
This is not simply a tax advantage - it’s a way to access the right scientific partner while optimising investment.
Supporting French innovation with an integrated European mode
For French biotech and pharma companies looking to combine scientific excellence, operational efficiency, and CIR optimisation, hVIVO provides a unique partnership model: a purpose‑built early‑phase engine, now fully accessible under the CIR scheme.
If you’d like to explore how CIR‑eligible outsourcing can support your next programme, our team would be happy to discuss the details - contact us via bd@hvivo.com or use the 'contact us form'.
